NYSVMS eNews
DVM360
Officials with the FDA have extended the comment period for draft guidance for industry (GFI) on defining durations for the use of certain antimicrobial drugs for animals, in response to requests from stakeholders. The comment period for Draft GFI #273 is now scheduled to close on January 5, 2024. Draft GFI #273, Defining Durations of Use for Approved Medically Important Antimicrobial Drugs Fed to Food-Producing Animals, was released September 25, 2023. At that time, there were nearly 100 approved applications for animal drugs. The GFI provides recommendations on how sponsors of animal drugs without a defined duration of use can voluntarily establish a defined duration of use for certain antimicrobial therapies that are considered medically important.
As 2023 ends, NYSVMS would like to wish all of you a happy holiday season! As we reflect on the past year, we would like to provide you a look back at the most accessed articles of the year. eNews will resume Thursday, Jan. 4, 2024.
DVM360
Officials with the FDA have extended the comment period for draft guidance for industry (GFI) on defining durations for the use of certain antimicrobial drugs for animals, in response to requests from stakeholders. The comment period for Draft GFI #273 is now scheduled to close on January 5, 2024. Draft GFI #273, Defining Durations of Use for Approved Medically Important Antimicrobial Drugs Fed to Food-Producing Animals, was released September 25, 2023. At that time, there were nearly 100 approved applications for animal drugs. The GFI provides recommendations on how sponsors of animal drugs without a defined duration of use can voluntarily establish a defined duration of use for certain antimicrobial therapies that are considered medically important.
As 2023 ends, NYSVMS would like to wish all of you a happy holiday season! As we reflect on the past year, we would like to provide you a look back at the most accessed articles of the year. eNews will resume Thursday, Jan. 4, 2024.
DVM360
The USDA has granted a conditional license to Dalan Animal Health, Inc. for a first-in-class vaccine to protect honeybees against American Foulbrood disease caused by Paenibacillus larvae. According to Dalan Animal Health—a biotech company in Athens, Georgia, aiming to advance insect health—honeybees are plagued by American Foulbrood, with previously no safe and sustainable solution for disease prevention. Trevor Tauzer, owner of Tauzer Apiaries and board member of the California State Beekeepers Association, noted that the vaccination is an exciting step forward for beekeepers.
As 2023 ends, NYSVMS would like to wish all of you a happy holiday season! As we reflect on the past year, we would like to provide you a look back at the most accessed articles of the year. eNews will resume Thursday, Jan. 4, 2024.
Morris Animal Foundation
A new study hopes to change the outcomes for Doberman pinschers affected by chronic hepatitis, a serious and sometimes fatal progressive inflammatory disease of the liver. The study, funded by Morris Animal Foundation, will be conducted by a veterinary research team at Utrecht University, the Netherlands. Led by Dr. Hille Fieten, Assistant Professor, Department of Clinical Sciences, the team first will look for genetic changes that influence development of hepatitis in Dobermans. The results could help breeders make informed breeding decisions. In addition, researchers will use banked study samples to look for biomarkers of disease with the goal of developing an early disease-detection test.
As 2023 ends, NYSVMS would like to wish all of you a happy holiday season! As we reflect on the past year, we would like to provide you a look back at the most accessed articles of the year. eNews will resume Thursday, Jan. 4, 2024.
AVMA
Almost half of dogs over the age of 10 will develop cancer. However, formal guidelines for earlier detection of cancer through regular screening programs do not exist in veterinary medicine. New research from PetDx, a San Diego–based molecular diagnostics company that developed a liquid biopsy test for cancer in dogs, provides reference data to help inform the optimal age when cancer screening might be considered in dogs of various breeds and weights. The findings were published Feb. 1 in the open-access journal PLOS One.
As 2023 ends, NYSVMS would like to wish all of you a happy holiday season! As we reflect on the past year, we would like to provide you a look back at the most accessed articles of the year. eNews will resume Thursday, Jan. 4, 2024.
FDA
The U.S. Food and Drug Administration approved Tauramox, the first generic moxidectin injectable solution indicated for beef and nonlactating dairy cattle for the treatment and control of internal and external parasites in cattle. Tauramox is an antiparasitic drug that contains the same concentration of moxidectin in the same injectable dosage form as the approved brand name drug product, Cydectin, which was first approved on May 20, 2005. As with Cydectin, residues in food products derived from beef and nonlactating dairy cattle treated with Tauramox will not represent a public health concern when the product is used according to the label.
As 2023 ends, NYSVMS would like to wish all of you a happy holiday season! As we reflect on the past year, we would like to provide you a look back at the most accessed articles of the year. eNews will resume Thursday, Jan. 4, 2024.
AVMA
Elanco’s Varenzin-CA1 is the first drug for the control of nonregenerative anemia associated with chronic kidney disease (CKD) in cats for which the Food and Drug Administration (FDA) has granted conditional approval, the agency announced May 1. Varenzin-CA1 is available only by prescription from a licensed veterinarian. CKD is a disease that requires day-to-day management in cats, and nonregenerative anemia is a complication that often contributes to death or euthanasia of affected cats because of poor quality of life. Cats with CKD develop nonregenerative anemia when their kidneys produce less of a hormone called erythropoietin, which helps the bone marrow produce red blood cells.
As 2023 ends, NYSVMS would like to wish all of you a happy holiday season! As we reflect on the past year, we would like to provide you a look back at the most accessed articles of the year. eNews will resume Thursday, Jan. 4, 2024.
DVM360
A new economic report commissioned by the Human Animal Bond Research Institute (HABRI) examined the health care cost savings associated with pet ownership in the United States. Overall, the report found that pet ownership could save the United States health care system $22.7 billion annually. The report, made possible by a grant from Banfield Pet Hospital, was co-authored by Terry L. Clower, PhD and Tonya E. Thornton, PhD, MPPA, both of whom have extensive expertise in economic and public policy research, according to a release from HABRI.
Recent Comments